{"allTrials": {"@totalCount": "3", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2012-09-28T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2007-11-22T00:00:00.000Z", "#text": "37381706"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Efficacy of three nutraceutical products of herbal origin in weight management of obese human subjects: a randomised, double blind, placebo controlled clinical study", "scientificTitle": null, "acronym": "Anti-obese Nutraceuticals", "studyHypothesis": "Public Title: Clinical efficacy of three nutraceutical products of herbal origin in obese subjects\n\nSupplementation of three natural polyherbal formulations will be helpful for management of weight control in obese human subjects.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Physical/anthropometric parameters:\n1.1. Body weight\n1.2. Body mass Index\n1.3. Waist hip ratio\n2. Biochemical parameters (serum/plasma):\n2.1. Fasting glucose\n2.2. Fasting insulin\n2.3. Triglyceride\n2.4. Cholesterol\n2.5. High Density Lipoprotein (HDL) cholesterol\n2.6. Low Density Lipoprotein (LDL) cholesterol\n\nThe primary and secondary outcomes will be measured on baseline, 14th day, 28th day and 56th day.", "secondaryOutcome": "Obesity biomarkers (serum/plasma):\n1. Leptin\n2. Glucagon like peptide-1\n3. Adiponectin\n4. Ghrelin\n\nThe primary and secondary outcomes will be measured on baseline, 14th day, 28th day and 56th day.", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from the Internal Review Board of ASR Academy of Medical Sciences (India) on the 5th October 2007 (ref: 07-01/IB/PHF Ob)."}, "externalRefs": {"doi": "10.1186/ISRCTN37381706", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "07/001/PHF Ob"}, "trialDesign": {"studyDesign": "This is a randomised, double blind, placebo-controlled study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-11-15T00:00:00.000Z", "overallEndDate": "2008-01-20T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "India"}, "trialCentres": {"trialCentre": {"@id": "25165912-c1f0-42f5-b05d-344f4bf3b61b", "name": "Department of General Medicine", "address": null, "city": "Eluru", "state": null, "country": "India", "zip": "534 002"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Adults aged 21 - 50 years\n2. Body Mass Index (BMI) greater than or equal to 30 kg/m^2 \n3. Willingness to participate in an exercise-walking program, supervised by a trained exercise specialist\n4. Willingness to consume the prescribed study diet of approximately 2,000 KCal per day as outlined in the protocol (meals will be provided at free of cost by the study sponsor)\n5. Written informed consent to participate in the trial\n6. Willingness to complete standard health history questionnaire before induction into the study\n7. Willingness to participate in five clinic visits (screening, baseline, 2, 4 & 8 weeks)\n8. If female:\n8.1. Should be negative in pregnancy test \n8.2. If of childbearing potential, should agree to follow an acceptable method of birth control for the duration of the study, such as condoms, foams, jellies, diaphragm, Intrauterine Device (IUD), etc.\n8.3. Postmenopausal for at least 1 year\n8.4. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "100", "totalFinalEnrolment": null, "totalTarget": "100", "exclusion": "1. History of thyroid disease or cardiovascular disease or diabetes\n2. Any other clinically significant disorder\n3. History of allergy to spices and herbal products\n4. Intractable obesity or uncontrolled body weight, BMI greater than 40 kg/m^2\n5. Presently using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss\n6. Recent, unexplained weight loss or gain\n7. Positive Human Immunodeficiency Virus (HIV) test\n8. History of hepatitis, pancreatitis, lactic acidosis or hepatomegaly with steatosis\n9. History of motor weakness or peripheral sensory neuropathy \n10. Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations", "patientInfoSheet": null, "recruitmentStart": "2007-11-15T00:00:00.000Z", "recruitmentEnd": "2008-01-20T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Obesity", "diseaseClass1": "Nutritional, Metabolic, Endocrine", "diseaseClass2": "Obesity"}}, "interventions": {"intervention": {"description": "A total of 100 human subjects is randomised and divided into four groups:\n1. Adipolean \n2. Adipolite \n3. Betelean\n4. Placebo\n\nThe treatment dosage is 1500 mg day, consisting of three 500 mg doses daily for the active treatment groups. Each subject in the fourth group will receive color matched equal amount of placebo per day.\n\nThe study duration will be 56 days. The visits and the evaluations will be at the baseline, 14th day, 28th day, and the 56th day.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Adipolean, Adipolite, Betelean"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22995673 results", "publicationStage": "Results", "biomedRelated": "true", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "73db1e3d-19a9-459a-85a5-ac1aa4d6de59", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2012-09-20T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/22995673"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": "Funder17273-0", "contactId": "Contact55234_17273", "sponsorId": "Sponsor53802"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55234_17273", "title": "Dr", "forename": "Artatrana", "surname": "Mishra", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Department of General Medicine\nASR Academy of Medical Sciences", "city": "Eluru", "country": "India", "zip": "534 002", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor53802", "organisation": "Laila Nutraceuticals (India)", "website": null, "sponsorType": "Industry", "contactDetails": {"address": "Unit-6 & 7\nPhase-III\nJawahar Autonagar", "city": "Vijayawada", "country": "India", "zip": "520007", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.487312.b", "rorId": "https://ror.org/05q6g7072"}, "funder": {"@id": "Funder17273-0", "name": "Laila Nutraceuticals (India)", "fundRef": null}}, {"trial": {"@lastUpdated": "2012-09-28T00:00:00.000Z", "@version": "25", "isrctn": {"@dateAssigned": "2007-09-07T00:00:00.000Z", "#text": "54186735"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "A phase-IV randomised, double blind comparative evaluation of immunogenicity of Monovalent Type 1 Oral Poliomyelitis Vaccine (mOPV1) versus trivalent OPV (tOPV): four-armed study", "scientificTitle": null, "acronym": null, "studyHypothesis": "This study aims to demonstrate the superiority of one dose of Monovalent Type 1 Oral Poliomyelitis Vaccine (mOPV1) compared to trivalent Oral Poliomyelitis Vaccine (tOPV).", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Seroconversion 30 days after a single dose of tOPV or mOPV1.", "secondaryOutcome": "Seroconversion after two doses of vaccine (one of three mOPV1 vaccines and tOPV).", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval received from:\n1. World Health Organization Research Ethics Review Committee (WHO ERC) on the 3rd September 2007 (ref: RPC241)\n2. MGM Medical College and Associated Hospital Society Indore on the 7th August 2007\n3. Osmania Medical College Koti, Hyderabad on the 10th August 2007"}, "externalRefs": {"doi": "10.1186/ISRCTN54186735", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "RPC241"}, "trialDesign": {"studyDesign": "Clinical trial, interventional, randomised, double blind four-armed comparative study", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-09-08T00:00:00.000Z", "overallEndDate": "2008-03-08T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["India", "Switzerland"]}, "trialCentres": {"trialCentre": {"@id": "86a72e7d-d90c-4463-aaa8-4e82fd295596", "name": "World Health Organization", "address": null, "city": "Geneva 27", "state": null, "country": "Switzerland", "zip": "CH-1211"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Healthy infants (greater than or equal to 2.5 kg birth weight, apgar score at 5 minutes greater than or equal to 9)\n2. Born at study sites (maternity hospitals)\n3. Residing less than 30 km away from study site\n4. Not planning to travel during entire study period (birth to 2 months)", "ageRange": "Child", "gender": "Both", "targetEnrolment": "720", "totalFinalEnrolment": null, "totalTarget": "720", "exclusion": "1. Newborns requiring hospitalisation\n2. Birth weight less than 2.5 kg\n3. Apgar score at 5 minutes less than 9\n4. Residence greater than 30 km from study sites\n5. Families expecting to be absent during the 60 day study period \n6. A diagnosis or suspicion of immunodeficiency disorder (either in participant or immediate family member)", "patientInfoSheet": null, "recruitmentStart": "2007-09-08T00:00:00.000Z", "recruitmentEnd": "2008-03-08T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Polio", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Polio"}}, "interventions": {"intervention": {"description": "Control group: 2 drops (approximately 0.1 ml) standard dose tOPV manufactured by Panacea at birth and 30 days of age\nIntervention group 1: 2 drops (approximately 0.1 ml) standard potency mOPV1 manufactured by Panacea at birth and 30 days of age\nIntervention group 2: 2 drops (approximately 0.1 ml) higher potency mOPV1 manufactured by Panacea at birth and 30 days of age\nIntervention group 3: 2 drops (approximately 0.1 ml) standard dose mOPV1 manufactured by Sanofi Pasteur at birth and 30 days of age\n\nBlood collection at birth (cord blood), further venipuncture blood collection at 30 days and at 60 days.\n\nContact details for Principal Investigator:\nDr T Jacob John\n439 Civil Supplies Godown Lane\nKamalakshipuram, Vellore\nTamil Nadu, 632002\nIndia\nTel: +91 (0)41 6226 7364\nFax: +91 (0)41 6223 2035 (courtesy of CMC Hospital)\nEmail: vlr_tjjohn@sancharnet.in", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase IV", "drugNames": "Monovalent Type 1 Oral Poliomyelitis Vaccine (mOPV1), trivalent Oral Poliomyelitis Vaccine (tOPV)."}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/21641951 results", "publicationStage": "Results", "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": {"@id": "72b62926-8a79-43e1-ac69-7e020b985b22", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2011-08-05T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/21641951"}, "description": "results", "productionNotes": null}}, "parties": {"funderId": ["Funder16915-0", "Funder16915-1", "Funder16915-2"], "contactId": "Contact54876_16915", "sponsorId": "Sponsor53435"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact54876_16915", "title": "Dr", "forename": "Roland", "surname": "Sutter", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "World Health Organization \n20 Avenue Appia", "city": "Geneva 27", "country": "Switzerland", "zip": "CH-1211", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+41 (0)22 791 4682"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "sutterr@who.int"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor53435", "organisation": "Panacea Biotec Limited (India)", "website": "http://www.panacea-biotec.com/", "sponsorType": "Industry", "contactDetails": {"address": "c/o Dr Arani Chatterjee\nB-1 Extn/G-3\nMohan Co-op Indl. Estate\nMathura Road", "city": "New Delhi", "country": "India", "zip": "110044", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+91 (0)11 4167 8000 or 4167 9000"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "aranichatterjee@panaceabiotec.com"}}, "privacy": "Public", "gridId": "grid.465005.2", "rorId": "https://ror.org/01ew11x49"}, "funder": [{"@id": "Funder16915-0", "name": "Panacea Biotec Limited (India)", "fundRef": null}, {"@id": "Funder16915-1", "name": "Gates Foundation (USA)", "fundRef": null}, {"@id": "Funder16915-2", "name": "World Health Organization (WHO) Polio Eradication Initiative", "fundRef": null}]}, {"trial": {"@lastUpdated": "2012-09-28T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2006-02-14T00:00:00.000Z", "#text": "11076857"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Preventive effects of Transmural Integrated Care (TIC, 'ketenzorg') on disabled persons within homes of the elderly", "scientificTitle": null, "acronym": "Pikov", "studyHypothesis": "Transmural integrated care is effective on quality of life, functional health and disability.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "1. Quality adjusted life years\n2. Functional health\n3. Disability\n4. Cost effectiveness", "secondaryOutcome": "1. Admission to hospital and nursing home\n2. Mortality\n3. Patients care satisfaction", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Received from local medical ethics committee"}, "externalRefs": {"doi": "10.1186/ISRCTN11076857", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NTR544"}, "trialDesign": {"studyDesign": "Multicentre randomised open label active controlled crossover group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Other"}, "trialTypes": {"trialType": "Quality of life"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2006-01-01T00:00:00.000Z", "overallEndDate": "2008-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "0d18feb9-3e96-4635-b1c4-ced3bcfe7eb7", "name": "Westfriese Zorggroep de Omring", "address": null, "city": "Hoorn", "state": null, "country": "Netherlands", "zip": "1624 AB"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Persons who have at least one chronic disorder and are ADL-disabled.", "ageRange": "Senior", "gender": "Both", "targetEnrolment": "166", "totalFinalEnrolment": null, "totalTarget": "166", "exclusion": "Terminally ill", "patientInfoSheet": null, "recruitmentStart": "2006-01-01T00:00:00.000Z", "recruitmentEnd": "2008-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Activities of daily living (ADL) disabled, chronic disorder", "diseaseClass1": {"@xmlns:isrctn": "http://www.67bricks.com/isrctn", "#text": "Other"}, "diseaseClass2": null}}, "interventions": {"intervention": {"description": "TIC is operationalised in three sequential elements:\n1. An in home multidimensional assessment is carried out by trained staff of the patient's functional health and care needs with the resident assessment instrument (RAI)\n2. The assessment outcomes are discussed in a multidisciplinary consultation (MC). The MC presents individualised care plans to manage or treat modifiable disabilities and risk factors. \n3. Consultation by a nursing home physician and psychologist is offered to the frailest residents at risk for nursing home admission (according to the RAI)\n\nThe control subjects receive care as usual.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2008 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/18606020 protocol\n2011 Results article in http://www.ncbi.nlm.nih.gov/pubmed/21708967 results\n2012 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/22655047 cost-effectiveness analysis", "publicationStage": "Results", "biomedRelated": "true", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": [{"@id": "3793e9b1-150e-4ed6-b4b4-08c7bf265e46", "@outputType": "protocolarticle", "@artefactType": "ExternalLink", "@dateCreated": "2008-07-07T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/18606020"}, "description": "protocol", "productionNotes": null}, {"@id": "0938986f-fe4c-42d7-8aa8-4b77a84d9198", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2011-08-09T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/21708967"}, "description": "results", "productionNotes": null}, {"@id": "326cbf90-a96f-47c2-acff-ed933eaa667f", "@outputType": "otherpublications", "@artefactType": "ExternalLink", "@dateCreated": "2012-08-01T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "http://www.ncbi.nlm.nih.gov/pubmed/22655047"}, "description": "cost-effectiveness analysis", "productionNotes": null}]}, "parties": {"funderId": ["Funder14803-0", "Funder14803-1", "Funder14803-2"], "contactId": "Contact52573_14803", "sponsorId": "Sponsor51097"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact52573_14803", "title": "Dr", "forename": "M.", "surname": "Boorsma", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Westfriese Zorggroep de Omring\nVerpleeghuis Lindendael\nKoepoortsweg 35", "city": "Hoorn", "country": "Netherlands", "zip": "1624 AB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "ma.boorsma@wxs.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor51097", "organisation": "West Fresian Area Care Group (Westfriese Zorggroep de Omring) (Netherlands)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "Lindendael Nursing Home (Verpleeghuis Lindendael)\nKoepoortsweg 35", "city": "Hoorn", "country": "Netherlands", "zip": "1624 AB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.487432.e", "rorId": "https://ror.org/0180s3q15"}, "funder": [{"@id": "Funder14803-0", "name": "VU University Medical Centre (VUMC) (Netherlands)", "fundRef": null}, {"@id": "Funder14803-1", "name": "Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)", "fundRef": "http://dx.doi.org/10.13039/501100001826"}, {"@id": "Funder14803-2", "name": "West Fresian Area Care Group (Westfriese Zorggroep de Omring) (Netherlands)", "fundRef": null}]}]}}